Nirogacestat for Kaposi Sarcoma

This trial tests the effectiveness of the drug nirogacestat for individuals with skin Kaposi sarcoma (KS), a cancer that forms lesions on the skin. The drug targets specific proteins to potentially stop and kill tumor cells. Researchers aim for nirogacestat to shrink these lesions and prevent their spread. Individuals with skin KS that hasn't improved in the last month and have at least six lesions might be suitable for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

You may need to stop certain medications before joining the trial. Specifically, you cannot take zidovudine, protease inhibitors, efavirenz, etravirine, and several other drugs listed in the exclusion criteria. If you're on these medications, you might need to switch to alternatives.

Previous studies have tested nirogacestat on patients with desmoid tumors, a different type of cancer. The safety results from these studies have been very encouraging. Research shows that patients could take nirogacestat for an average of nearly three years, indicating that the treatment is generally well-tolerated over a long period.

However, like most treatments, nirogacestat can have side effects. Past studies reported some negative effects, but these were not serious enough to halt the trials. The drug has been fast-tracked for FDA approval due to its effectiveness in other conditions, suggesting a good safety record.

Most treatments for Kaposi Sarcoma focus on targeting the cancer cells directly or boosting the immune system, such as with chemotherapy or antiretroviral therapy. But Nirogacestat works differently, targeting a specific protein called gamma-secretase, which plays a role in tumor growth. This unique mechanism of action might make it effective in stopping the progression of Kaposi Sarcoma in a new way. Researchers are excited about Nirogacestat because it could offer a targeted approach, potentially with fewer side effects compared to broader, more aggressive treatments.

Research has shown that nirogacestat may help treat Kaposi sarcoma (KS). In earlier studies, nirogacestat shrank tumors and slowed their spread. Approximately 45.7% of patients responded to the treatment, with their tumors either shrinking or disappearing. Nirogacestat blocks certain proteins that aid tumor growth, potentially preventing the disease from worsening. This trial will evaluate nirogacestat as a potential option for managing KS.¹²³⁴⁶